SEC Filing Summary: Form 10-Q, Quarter Ended March 31, 2022
Entity note: The supplied filing is for Health Sciences Acquisitions Corporation 2, a Cayman Islands SPAC—not Orchestra Biomed Holdings, Inc. The summary below reflects the filing’s named registrant.
Business context
The registrant was a blank-check company seeking a business combination, with a stated focus on healthcare innovation. It had not begun operations or generated operating revenue. Its principal assets were funds held in trust pending a transaction.
Financial highlights
| Metric | Q1 2022 / March 31, 2022 | Comparable period / prior date |
|---|---|---|
| Operating revenue | None | None |
| Net loss | $437,689 | $108,002 loss in Q1 2021 |
| General and administrative expense | $421,954 | $81,948 in Q1 2021 |
| Administrative fee to related party | $30,000 | $30,000 in Q1 2021 |
| Trust investment income | $14,265 | $3,946 in Q1 2021 |
| Net cash used in operating activities | $335,580 | $76,374 in Q1 2021 |
| Cash outside trust | $1,418,880 | $1,754,460 at December 31, 2021 |
| Trust account investments | $160,036,712 | $160,022,447 at December 31, 2021 |
| Working capital | Approximately $1.2 million | — |
| Total liabilities | $5,906,538, including $5.6 million deferred underwriting commissions | $5,765,539 at December 31, 2021 |
Margins are not meaningful because the company had no operating revenue. The filing reports no outstanding working-capital loans. Public shares subject to possible redemption—16 million shares at $10 per share, or $160 million—are classified as temporary equity, not debt.
Changes versus the prior comparable period
- Net loss increased by $329,687 year over year, mainly as general and administrative expense rose by $340,006.
- Operating cash use increased by $259,206 year over year.
- Cash outside the trust declined by approximately $336,000 from year-end 2021; trust assets increased modestly.
Outlook, risks, and unusual items
- The company had until August 6, 2022, unless shareholders approved an extension, to complete a business combination. Failure to do so would trigger winding up and liquidation; public shareholders would generally receive their pro rata share of the trust account.
- Management expected available working capital and borrowing capacity to cover needs through the earlier of a business combination or one year from the filing, but stated that the approaching mandatory liquidation raised substantial doubt about the company’s ability to continue as a going concern.
- The $5.6 million deferred underwriting commission was payable only if a business combination closed; underwriters waived it if the company liquidated without completing one.
- Management cited COVID-19 and the Russia-Ukraine conflict as uncertainties whose specific effects on the company were not determinable.
- Disclosure controls were ineffective due to a material weakness in accounting for complex financial instruments. The weakness had contributed to prior-period restatements. Management reported additional review procedures and ongoing remediation efforts; no material change in internal control was otherwise reported during the quarter.
- No legal proceedings or subsequent events requiring financial-statement adjustment were reported.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Health Sciences Acquisitions Corporation 2, not Orchestra Biomed Holdings, Inc.
- Check whether the SPAC completed a business combination or obtained an extension before the August 6, 2022 deadline.
- Assess the status and remediation of the material weakness and any related restatements or control improvements.
- Distinguish trust assets available for shareholder redemption from the much smaller operating cash balance.
- Review potential transaction costs and dilution, including deferred underwriting fees, sponsor arrangements, and warrants.